Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Feasibility of Autologous SVF for Osteoarthritis
NCT01885832Phase 2Withdrawn
- Sponsor
- Translational Biosciences
- Start
- Jun 2013
- Primary completion
- Jul 2016
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of autologous adipose-derived stromal vascular fraction in osteoarthritis (OA), sponsored by Translational Biosciences. Primary endpoint: Number of participants with adverse events at 6 months. Planned start Jun 2013; status: withdrawn.
02
Drugs
autologous adipose-derived stromal vascular fraction
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT01885832.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01885832.